DexCom, Inc. (NASDAQ:DXCM) EVP Matthew Vincent Dolan Sells 1,990 Shares

DexCom, Inc. (NASDAQ:DXCM) EVP Matthew Vincent Dolan sold 1,990 shares of DexCom stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the sale, the executive vice president now directly owns 42,377 shares in the company, valued at $5,839,974.37. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

DexCom Price Performance

Shares of DXCM opened at $130.71 on Friday. The firm has a market cap of $50.39 billion, a PE ratio of 99.78, a P/E/G ratio of 2.30 and a beta of 1.20. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The firm has a fifty day simple moving average of $129.55 and a two-hundred day simple moving average of $116.66. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.07. The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The company’s quarterly revenue was up 26.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.34 EPS. On average, equities analysts anticipate that DexCom, Inc. will post 1.76 EPS for the current year.

Analyst Ratings Changes

DXCM has been the topic of a number of analyst reports. Royal Bank of Canada initiated coverage on DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target on the stock. UBS Group boosted their price target on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Citigroup boosted their price target on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Raymond James boosted their price target on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 23rd. Finally, StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $141.40.

Institutional Investors Weigh In On DexCom

A number of hedge funds have recently added to or reduced their stakes in the stock. Centaurus Financial Inc. raised its stake in DexCom by 5.5% during the 1st quarter. Centaurus Financial Inc. now owns 1,236 shares of the medical device company’s stock valued at $632,000 after buying an additional 64 shares during the last quarter. Stableford Capital II LLC increased its stake in shares of DexCom by 2.1% in the 4th quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock worth $563,000 after purchasing an additional 88 shares in the last quarter. Fortis Capital Advisors LLC increased its stake in shares of DexCom by 5.5% in the 2nd quarter. Fortis Capital Advisors LLC now owns 1,744 shares of the medical device company’s stock worth $224,000 after purchasing an additional 91 shares in the last quarter. D Orazio & Associates Inc. increased its stake in shares of DexCom by 0.8% in the 4th quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock worth $1,534,000 after purchasing an additional 93 shares in the last quarter. Finally, Gulf International Bank UK Ltd increased its stake in shares of DexCom by 0.3% in the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock worth $4,448,000 after purchasing an additional 93 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.